AlphAIAlphAI — Financial news for AI agents
stockstotrade.com$GKOS

Glaukos (GKOS) Stock Surges After Massive Earnings Beat

Glaukos (GKOS) stock surged 32.57% on October 29, 2026, after reporting Q3 revenue of $211M (vs. $168M expected) and adjusted EPS of $0.47 (vs. projected loss). The company raised its 2026 revenue guidance to $775M–$785M and 2027 to $1.0B. Positive clinical data for iDose TR and Epioxa, along with a retinal deal, supported the rally. GKOS closed at $240.52, up from $181.43 the prior day. Analysts raised price targets, with BTIG at $205 and Mizuho at $190.

Original reporting
stockstotrade.com
Published Oct 29, 2026, 4:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 5:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Glaukos (GKOS) Stock Surges After Massive Earnings Beat — source image
Source · stockstotrade.com
Decision brief

The 30-second read

$GKOSBullishHigh
01

Why it matters

The earnings surprise is likely to attract short‑term buying, but investors should monitor margin trends and policy risk.

02

Market read

A mid‑cap biotech with a large intraday move; earnings beat provides fresh trading impetus.

03

What to watch

Potential reimbursement pressure from policy changes and the need for sustained clinical data to support long‑term growth.

Relevance 8/10Novelty 8/10Timing: today

Background

Glaukos (GKOS) posted a strong Q3 earnings beat, raising revenue guidance and highlighting positive trial data for iDose TR and Epioxa.

Company-level read

Ticker impact

$GKOSBullishHigh confidence
Context

Glaukos reported Q3 earnings that beat expectations with $211M revenue and $0.47 EPS, driving a 32.6% stock surge.

Expected impact

upward bias as traders price in the earnings surprise and raised guidance

Evidence & confidence

The surprise earnings and guidance reset expectations, and the stock already jumped 14% post‑print, indicating momentum.

Market effects

Sector

Biotech/ophthalmology sector may see broader rally on the earnings beat.

Regional

U.S. market gains from the surprise earnings in a Nasdaq‑listed medtech name.

Global

Limited to investors focused on U.S. biotech and ophthalmology stocks.

Counterpoint

What could challenge this read

The stock may be overbought after a rapid 30% move; valuation remains stretched and margins are still negative.

Key entities

  • company
    Glaukos Corporation

    U.S.-listed ophthalmology biotech that reported the earnings beat.

  • analyst
    BTG

    BTIG raised its price target on GKOS following the earnings.

Read at source← All news

StoryGlaukos reports record Q3 sales, beats expectations and lifts 2026‑2027 revenue outlook

Also covered by

5 outlets

Related articles

$MGRCMed

McGrath RentCorp Soars 9% as It Prepares to Join the S&P SmallCap 600

McGrath RentCorp (MGRC) shares rose 9% on Monday after being added to the S&P SmallCap 600 index. The company cut its revenue outlook last week and is increasing capital expenditure. S&P SmallCap 600 index funds must buy MGRC shares by November 4. Glaukos (GKOS) and Loar Holdings (LOAR) are also being added to the S&P MidCap 400 and S&P SmallCap 600, respectively.

finance.yahoo.com
$GKOSHighAI 9/10

Glaukos (GKOS) Stock Soars After Blowout Q3 Earnings Beat

Glaukos (GKOS) stock surged 33.65% after Q3 earnings beat expectations, reporting EPS of $0.47 vs. -$0.09 and revenue of $211M vs. $168.1M. The company raised FY26 and FY27 revenue guidance, citing strong performance of iDose TR and Epioxa. Analysts upgraded price targets, with BTIG at $205 and Mizuho at $190.

timothysykes.com
$GKOSHighAI 9/10

Glaukos (GKOS) Stock Surges After Earnings Beat And Bullish Guidance

Glaukos (GKOS) stock surged 32.65% after reporting Q3 earnings that beat expectations, with adjusted EPS of $0.47 vs. an expected loss. Revenue was $211M, exceeding the $168M consensus. The company raised its 2026 revenue guidance to $775M–$785M and set a 2027 target of $1.0B. Analysts maintained buy ratings with adjusted price targets.

timothysykes.com
$GKOSMedAI 8/10

Piper Sandler raises Glaukos stock price target on Epioxa strength

Piper Sandler raised its price target on Glaukos (GKOS) to $240 from $195, citing strong Q3 results. Revenue was $211.0M, up 58% YoY, beating estimates. The company also raised its fiscal 2026 revenue guidance to $775M-$785M. GKOS stock has surged 135% over the past year, trading near its 52-week high at $229.12. Other analysts also raised price targets, citing strong performance and pipeline progress.

investing.com